Work

Brigatinib (BRG) vs Crizotinib (CRZ) in Patients (Pts) With ALK Inhibitor-Naive Advanced ALK+ NSCLC from ALTA-1L

Year: 2019

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1093/annonc/mdz339.006

Authors: James C.H. Yang, Hye R. Kim, Myung-Ju Ahn, Ji-Youn Han, Maximilian J. Hochmair, Ki H. Lee, Angelo Delmonte, Maria R. Garcia Campelo, Dong-Wan Kim, Enriqueta Felip, Raffaele Califano, Alexander Spira, Scott Gettinger, Marcello Tiseo, Jeff Haney, David Kerstein, Sanjay Popat, D.R. Camidge

Institutions: National Taiwan University Hospital, Yonsei University, Severance Hospital, Samsung Medical Center, National Cancer Center, Ludwig Boltzmann Institute for Lung Health, Chungbuk National University, Chungbuk National University Hospital, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Complexo Hospitalario Universitario A Coruña, Seoul National University Hospital, Vall d'Hebron Hospital Universitari, The Christie NHS Foundation Trust, Virginia Cancer Specialists, Yale Cancer Center, University of Parma, Takeda Oncology (United States), Royal Marsden Hospital, University of Colorado Cancer Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2979998908

FWCI: 0.185

Cites:

Cited by: 1

Related to: 10